INTRODUCTION

*Helicobacter pylori*, a gram-negative spiral bacillus, is one of the most common bacterial pathogens worldwide (Suarez et al., 2006). *H. pylori* infection is associated with a range of gastrointestinal disorders, ranging from gastritis to gastric cancer (Ermis & Senocak Tasci, 2015). Standard triple therapy (STT) of clarithromycin, a proton pump inhibitor, and either metronidazole or amoxicillin for
1–2 weeks is used worldwide for treating H. pylori infection. It has a high eradication success rate of >80% (Gong et al., 2014). However, STT is associated with a number of side effects, including antibiotic resistance and relapse (Ermis & Senocak Tasci, 2015). Therefore, alternative agent with less serious side effects needs to be identified for the eradication of H. pylori and treatment of gastric disease.

*Rhus verniciflua* Stokes (*R. verniciflua*) is commonly known as the lacquer tree (Lee et al., 2015). *R. verniciflua* is traditionally used in oriental medicine for treating a variety of diseases. The plant is also consumed as an ingredient in sumac chicken and duck in Korea (Jeong et al., 2015). Urushiol is a major component in the sap of *R. verniciflua*. It has anti-inflammatory, antimicrobial, and antioxidant effects in mice (Bang et al., 2014). However, clinical trials of urushiol are hampered by the fact that it is a causative agent of allergic contact dermatitis (Lee et al., 2015).

Fermented-*Rhus verniciflua* extract (FRVE) is an urushiol-free extract fermented by *Fomitella fraxinea* (Choi et al., 2007). In a recent study, three phenolic acids (gallic acid, protocatechuic acid, and 4-hydroxy benzoic acid) and four flavonoids (fustin, fisetin, sulfuretin, and butein) have been detected in FRVE, with gallic acid and fisetin being its major compounds (Choi et al., 2012). FRVE also has anticancer, antioxidant, and anti-inflammatory effects. It can protect mice against hepatosteatosis (Choi et al., 2012). Antibacterial effect of FRVE is reported in recent studies. FRVE has growth inhibitory effect on *H. pylori* (Choi et al., 2016). And a study of antibacterial activity of major constituents which are methyl gallate, fustin, and quercitrin showed antibacterial effect of fustin and methyl gallate (Jang et al., 2016). A recent study has reported that fisetin has antibacterial effect (Leotoing et al., 2013). Moreover, gallic acid has antioxidant, antiproliferative, and antitumorigenic activities (Daglia et al., 2014). However, few have been reported about its effect on *H. pylori* has not been reported yet.

The objective of the present study was to determine the minimal inhibitory concentration of urushiol-free FRVE for *H. pylori* eradication. Reduction of *H. pylori* and improvement of gastritis after oral administration of FRVE were also compared to those by STT in C57BL/6 mice.

**MATERIALS AND METHODS**

**Fermented *R. verniciflua* extracts**

FRVE, a fermented extract of bark part of *R. verniciflua*, and its constituent compounds (Table 1) were provided by HS Choi at Rural Development Administration, Republic of Korea. FRVE comprises abundant fustin, fisetin, and gallic acid in MS. The method for preparing FRVE has been described by Choi previously (Choi et al., 2012). To absorb moisture in the lacquer bark, water was immersed for 1 day and drained for 1 day. Take out the lacquer bark, transfer it to a 5 L mushroom cultivation bag, put on a filter, and sterilize for 12 to 100 min. The prepared *F. fraxinea* mycelium was inoculated, cultured for 30 days at 21°C, and then dried with hot air at 50°C to prepare fermented lacquer. FRVE was manufactured in powder form for use in experiments. The concentration was calculated according to the solvent (distilled water).

**Minimal inhibitory concentrations**

*H. pylori* Sydney strain 1 (SS1) was obtained from *H. pylori* Korean Type Culture Collection (HpKTCC, Department of Microbiology, Gyeongsang University College of Medicine, Jinju, Korea). *H. pylori* was maintained on Mueller–Hinton agar containing 5% sheep blood (MH-BAP, Hangang, Gunpo, Korea) at 37°C with 10% CO2. Agar dilution method was used to determine minimal inhibitory concentrations (MICs). FRVE was subjected to serial dilution, yielding concentrations of 0.5 to 4 mg/ml. It was then mixed with MH-BAP. *H. pylori* was transported to half-plates from 72-hr-subs cul tured normal MH-BAP plates using smear culture method. Plates were incubated at 37°C in an incubator with 10% CO2. After incubation for 72 hr, MICs of FRVEs were evaluated and its appropriate concentration for in vivo study was determined. Rough surfaces of half plate suggest living organisms on its concentration and smooth surface means opposition.

**Animals**

All animals received humane care in this study. All procedures were conducted in accordance with National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. All procedures were approved by Institutional Animal Care and Use Committee of Hallym University College of Medicine (2013-131; 2014-71; 2015-21). Six-week-old specific pathogen-free male C57BL/6 mice were purchased from Dooyool Biotech (Seoul, Korea). All mice were housed individually in steel microisoler cages at 22 ± 2°C with 12 hr/12 hr of light/dark cycle. They were provided free access to water and food throughout the experiment period. They were monitored daily. These mice were divided into the following groups (Figure 1): no treatment (*n* = 10), HP (*H. pylori* infection, *n* = 10), HP + FRVE (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and treatment with FRVE, *n* = 50), HP + FRVE+triple (*H. pylori* infection and
treatment with FRVE + standard triple therapy, \( n = 10 \), and HP + triple (H. pylori infection and treatment with standard triple therapy \( n = 10 \)).

\( H. pylori \) SS1 was maintained on Brucella agar [28 g Brucella broth powder (R&D Systems, Minneapolis, MN, USA) with 15 g agar per liter] containing 10% horse serum (Thermo Fisher Scientific, Waltham, MA, USA) at 37°C in an incubator with 10% CO\(_2\). \( H. pylori \) was incubated for 72 hr and transferred to Brucella broth liquid containing 10% horse serum. Before infection, mice were fasted for 4 hr. Optical density of \( H. pylori \) suspension was adjusted to 10, corresponding to \( 6.7 \times 10^9 \) CFU/ml (Navabi et al., 2013). For standard triple therapy treatment, 400 mg/kg metronidazole, 20 mg/kg omeprazole, and 250 mg/kg clarithromycin were mixed in drinking water (Loughlin et al., 2003). Standard triple therapy was administered five times per week.

In the second week, mice in the four groups were infected with \( H. pylori \) for 2 weeks. In the fourth week, mice in the HP + FRVE group were divided into the following five subgroups and treated with 3, 4, 6, 8, or 16 mg/ml of FRVE suspension. Treatment of the FRVE suspension was performed 5 times per week for 3 weeks. Mice in the HP + FRVE+triple group were treated with 3 mg/ml of FRVE suspension for 3 weeks. In the fifth week, mice in the triple groups were treated with standard triple therapy for 2 weeks. Mice were euthanized in the seventh week.

**Histology**

A midline abdominal incision was performed, and the stomachs were collected for analysis. \( H. pylori \) infection was confirmed by rapid urease test kit or pathology confirmation. The stomach was incised along the greater curvature and fixed in 10% neutral buffered formalin. The tissue was embedded, cut at 5 \( \mu \)m, and stained with hematoxylin and eosin/giemsa staining. The degree
of inflammation of the gastric mucosa was measured based on the updated Sydney system (Dixon et al., 1996) using a 4-point scale for grading *H. pylori* and inflammation severity: grade 0, normal; grade 1, mild; grade 2, moderate; and grade 3, severe. A histologist who was blinded to experimental conditions analyzed all specimens.

**Cytokine**

Stomach tissue was homogenized using a complete Bio-Plex Cell Lysis Kit (Bio-Rad, Hercules, CA, USA). Homogenization was performed using 100 μL of cell lysis buffer and 500 μL PBS per 100 mg tissue. Expression of proinflammatory cytokines in stomach tissue

**FIGURE 2** MIC of FRVEs in vitro. *H. pylori* was cultured in half-right side of MH-BAP with (a) 0 mg/ml FRVE; (b) 1 mg/ml FRVE; (c) 1.5 mg/ml FRVE; (d) 2 mg/ml FRVE; (e) 3 mg/ml FRVE; and (f) 4 mg/ml FRVE. *H. pylori* proliferation was unaffected by 1 or 1.5 mg/ml of FRVE. FRVE, fermented-Rhus verniciflua extract

**FIGURE 3** *H. pylori* colonization of histological analysis in mice treated with FRVE after *H. pylori* infection during 2 weeks. Mice were infected *H. pylori* for 2 weeks and treated with FRVE. (a) Mean grade of antrum and corpus, (b) percentage of grade on antrum, and (c) representative images of colonized *H. pylori* of Giemsa staining in stomach of mice. (d) Percentage of response in rapid urease test. In HP, HP + FRVE, and HP + triple therapy group, *H. pylori* are located in the mucus of outer mucosal layer (arrow). *p < .05; **p < .01. FRVE, fermented-Rhus verniciflua extract
and serum was analyzed by enzyme-linked immunosorbent assay (ELISA, Bio-Plex Pro Mouse Cytokine Assay Kit, Bio-Rad) according to the manufacturer’s instructions.

**Statistical analysis**

Statistical analysis was performed using Prism V.5.0 (GraphPad, San Diego, CA, USA) and SPSS, V.18.0 (SPSS Inc., Chicago, IL, USA). Differences in \( H. \) pylori colonization grade, inflammation grade, and cytokine expression level among groups were calculated by one-way analysis of variance (ANOVA) and Tukey’s post hoc test. A \( P \) value of less than 0.05 was considered statistically significant.

**RESULTS**

**Minimal inhibitory concentrations of FRVEs and \( H. \) pylori eradication**

FRVE at 2 to 4 mg/ml eradicated \( H. \) pylori. However, \( H. \) pylori proliferation was unaffected by 1 or 1.5 mg/ml of FRVE (Figure 2). Treatment with 2 mg/ml of FRVE reduced \( H. \) pylori grade in mice (data not shown). Thus, treatment with a high concentration of FRVE might eradicate \( H. \) pylori. To test this possibility, mice were treated with 3, 4, 6, 8, or 16 mg/ml of FRVE for 3 weeks.

In the analysis of antrum and corpus, \( H. \) pylori colonization in HP group had a mean grade of 2.2 ± 0.8 (20% mild, 40% moderate, and 40% severe) (Figure 3). \( H. \) pylori colonization in HP + FRVE 3 mg/ml

![Figure 4](image)

**FIGURE 4** Gastric inflammation of histological analysis in mice treated FRVE after \( H. \) pylori infection. Mice were infected \( H. \) pylori for 3 weeks and treated the FRVE. (a) Mean grade of antrum and corpus, (b) percentage of grade on antrum, and (c) representative images of inflammation in stomach of mice. In HP, HP + FRVE, and HP + triple therapy group, neutrophil and mononuclear cells are infiltrated in the stomach wall (black arrow). Significances are shown above bars; *\( p < .05; ** p < .01\)
subgroup had a mean grade of 1.4 ± 0.5. *H. pylori* colonization in subgroup of HP + FRVE 4 mg/ml had a mean grade of 1.2 ± 0.4. *H. pylori* colonization in subgroup of HP + FRVE 3 mg/ml and HP + FRVE 4 mg/ml tended to be less severe than that in HP group. *H. pylori* colonization in subgroup of HP + FRVE 6 mg/ml had a mean grade of 0.2 ± 0.4. *H. pylori* colonization in subgroup of HP + FRVE 8 mg/ml had a mean grade of 0.6 ± 0.5. *H. pylori* colonization in subgroup of HP + FRVE 16 mg/ml had a mean grade of 0.5 ± 0.5. The subgroups of HP + FRVE 6 mg/ml, HP + FRVE 8 mg/ml, and HP + FRVE 16 mg/ml showed significantly (p < .01) lower *H. pylori* colonization than that in HP group. *H. pylori* colonization in subgroup of HP + FRVE 6 mg/ml, HP + FRVE 8 mg/ml, and HP + FRVE 16 mg/ml tended to be less severe than that in HP group. *H. pylori* colonization in subgroup of HP + FRVE 4 mg/ml had a mean grade of 1.2 ± 0.4. *H. pylori* colonization in subgroup of HP + FRVE 3 mg/ml and HP + FRVE 4 mg/ml tended to be less severe than that in HP group. *H. pylori* colonization in subgroup of HP + FRVE 6 mg/ml had a mean grade of 0.2 ± 0.4. *H. pylori* colonization in subgroup of HP + FRVE 8 mg/ml had a mean grade of 0.6 ± 0.5. *H. pylori* colonization in subgroup of HP + FRVE 16 mg/ml had a mean grade of 0.5 ± 0.5. The subgroups of HP + FRVE 6 mg/ml, HP + FRVE 8 mg/ml, and HP + FRVE 16 mg/ml showed significantly (p < .01) lower *H. pylori* colonization than that in HP group. *H. pylori* colonization in subgroup of HP + FRVE 6 mg/ml, HP + FRVE 8 mg/ml, and HP + FRVE 16 mg/ml tended to be less severe than that in HP group. *H. pylori* colonization in subgroup of HP + FRVE 4 mg/ml had a mean grade of 1.4 ± 0.5. *H. pylori* colonization in subgroup of HP + FRVE 3 mg/ml and HP + FRVE 4 mg/ml tended to be less severe than that in HP group. *H. pylori* colonization in subgroup of HP + FRVE 6 mg/ml had a mean grade of 0.2 ± 0.4. *H. pylori* colonization in subgroup of HP + FRVE 8 mg/ml had a mean grade of 0.6 ± 0.5. *H. pylori* colonization in subgroup of HP + FRVE 16 mg/ml had a mean grade of 0.5 ± 0.5. The subgroups of HP + FRVE 6 mg/ml, HP + FRVE 8 mg/ml, and HP + FRVE 16 mg/ml showed significantly (p < .01) lower *H. pylori* colonization than that in HP group. *H. pylori* colonization in both HP + FRVE+triple and HP + triple group showed significantly lower grade compared to that in HP group (p < .05).

Rapid urease test revealed that eradication rates of *H. pylori* by FRVE was dose-dependent (Figure 3). HP and HP + FRVE 3 mg/ml showed 100% of positive reaction for gastric *H. pylori*. However, HP + FRVE 4 mg/ml and HP + FRVE 6 mg/ml showed 50% and 60% negative reaction for gastric *H. pylori*, respectively. HP + FRVE 8 mg/ml and HP + FRVE 16 mg/ml had 40% and 50% negative reaction for gastric *H. pylori*, respectively. HP + FRVE+triple and HP + triple group showed 40% and 20% negative reaction for gastric *H. pylori*, respectively. These results were similar to those of histological analysis. Especially, 6 mg/ml FRVE effectively reduced *H. pylori* grade and increased *H. pylori* eradication rate. Moreover, HP + FRVE+triple showed superior eradication rate than HP + FRVE 3 mg/ml or HP + triple therapy. These results were similar to those of *H. pylori* grade based on histological analysis.

**Improvement in gastritis**

Regarding inflammation improvement, inflammation in HP had a mean grade of 1.6 ± 0.5 (Figure 4). This finding was shown on antrum analysis not corpus. Inflammation in subgroup of HP + FRVE 3 mg/ml had a mean grade of 1.4 ± 0.5. Inflammation in subgroup of HP + FRVE 4 mg/ml had a mean grade of 1.2 ± 0.4. Inflammation grade in subgroup of HP + FRVE 3 mg/ml or HP + FRVE 4 mg/ml tended to be lower than that in HP group. Inflammation in subgroup of HP + FRVE 6 mg/ml had a mean grade of 0.4 ± 0.5, which was significantly (p < .01) lower than in HP group. Inflammation in subgroup of HP + FRVE 8 mg/ml had a mean grade of 0.8 ± 0.4. Inflammation in subgroup of HP + FRVE 16 mg/ml also had a mean grade of 0.8 ± 0.4. Inflammation grades in HP + FRVE 8 mg/ml and HP + FRVE 16 mg/ml subgroups tended to be lower than that in HP group. However, they were higher than that in HP + FRVE 6 mg/ml subgroup. Inflammation grade in HP + triple group was 1.0 (100% mild), similar to that in HP + FRVE 8 mg/ml and HP + FRVE 16 mg/ml subgroups. However, it was significantly (p < .05) lower than that in HP group. Inflammation in HP + FRVE+triple group had a mean grade of 0.4 ± 0.5, similar to that in HP + FRVE 6 mg/ml subgroup. However, it was significantly (p < .01) lower than that in HP group. No gastric inflammation was detected in the control group without any treatment.

**Inflammatory cytokine**

After *H. pylori* infection for 2 weeks, TNF-α concentrations did not differ significantly among groups (Figure 5). However, IL-1β concentration in subgroup of HP + FRVE 8 and 16 mg/ml and HP + triple group was significantly lower than that in HP group.
DISCUSSION

In this study, the MIC of FRVE against H. pylori in vitro and the concentration that resulted in the greatest reduction in H. pylori grades and improvement of inflammation in vivo were investigated. Application of 2 mg/ml of FRVE was highly effective in vitro while 6 mg/ml of FRVE was highly effective animal study. In this study, FRVE contained higher level of fustin than other components (Table 1). Previous reports have demonstrated that fustin possesses cell proliferation-inhibiting and antiviral activities (Kang et al., 2012). Results for this study revealed that fustin also had antibacterial effect against H. pylori and anti-inflammatory activity. In our results, fustin revealed main component in the FRVE. In a previous report, fustin exerts neuroprotection from cell death and fustin flavonoid attenuates beta-amyloid (1–42)-induced learning impairment (Jin et al., 2009; Park et al., 2007). Fisetin alleviated kidney inflammation and apoptosis to protect against LPS-induced septic condition (Ren et al., 2020) and reduced inflammation on toxicity (Hytti et al., 2017). Gallic acid also has beneficial effects on various diseases including ulcer (Akbari, 2020; Zhou et al., 2020). Taken together, these findings suggest that FRVE has anti-H. pylori activity and consequently may be used as a supplementary agent or single agent in anti-H. pylori regimen, but further research is required for the clinical application.

Histological analysis by H&E and Giemsa staining with urease test using CLO test kit were used to detect H. pylori in this study. Interestingly, rapid urease test revealed that H. pylori eradication rate was increased by 6 mg/ml FRVE. FRVE at 6 mg/ml shown higher eradication rate (60%) compared to 0% in the control group. This rate (60%) was also higher than that (20%) of the standard triple therapy. This results suggest that FRVE may be used as a supplementary agent or single agent in anti-H. pylori regimen, but further research is required for the clinical application.

A reduction in H. pylori grades according to the upgraded Sydney system can protect against H. pylori-induced gastritis and gastric cancer (Schenk et al., 2000). Our results showed that H. pylori colonization grade in HP was decreased to 0.2 ± 0.4 after treatment with 6 mg/ml of FRVE. In addition, inflammation grade was decreased to 0.4 ± 0.5. These results suggest that H. pylori caused gastric inflammation can be ameliorated by FRVE. Therefore, FRVE might have the potential as a therapeutic agent for H. pylori-induced gastritis and gastric cancer.

Our results showed that application FRVE (a concentration of 6 or 3 mg/ml) together with standard triple therapy reduced H. pylori grades and improved inflammation. The standard triple therapy with proton pump inhibitor and antibiotics (amoxicillin, metronidazole, or clarithromycin) has been used to eradicate H. pylori for a long time, and resistance of H. pylori to these antibiotics has increased (Testerman & Morris, 2014). In this study, FRVE at 2 mg/ml eradicated H. pylori in vitro. This concentration is lower than those of antibiotics or proton pump inhibitors used in the standard triple therapy, in which higher doses of amoxicillin, metronidazole, and clarithromycin are used. Because the standard triple therapy has been used to eradicate H. pylori for a long time, resistance of H. pylori to these antibiotics has increased (Testerman & Morris, 2014). Our results showed that application FRVE at 6 or 3 mg/ml together with standard triple therapy reduced H. pylori grades and improved inflammation.

In the present work and in prior studies that used urushiol-free FRVE as a single treatment or repeated for 90 days, no toxicity was recorded (Shin et al., 2013). Safety evaluation conducted by the Rural Development Administration proved reliable safety in toxicity test, antigen test, repeated DRF skin test, and genetic toxicity test using rats and beagle dogs. Only vomiting that was not result from systemic toxicity was reported in a beagle dog with 2,000 mg/kg of urushiol-free FRVE. Therefore, FRVE is likely to be safe for use as an antibacterial agent. It has been reported that FRVE has anticancer, antigrowth, anti-inflammatory, antioxidant, antiviral, and neuroprotective effects in vitro (Choi et al., 2014; Sapkota et al., 2010). Therefore, FRVE has been subjected to clinical trials for various diseases (Lee et al., 2011).
Green tea, muscadine grape skin, broccoli, and cranberry have been investigated in vitro and/or in vivo as potential treatments for *H. pylori* (Brown et al., 2011). However, these studies did not make use of animal models and their concentrations were higher than 2 mg/ml, the concentration of FRVE used in this work. Thus, FRVE could be used as anti-*H. pylori* agent at a low concentration for a short period.

Gastric IL-1β expression is associated with *H. pylori* infection while urushiol therapy can reduce its expression (Lee et al., 2010; Suk et al., 2011). In our study, IL-1β level follows previous reports. However, TNF-α expression levels were not affected by FRVE. This might be due to the low concentration of sulfuretin present in FRVE. This suggests that FRVE might have exerted its beneficial effects through its direct cytotoxic effect on *H. pylori* rather than through expression of TNF-α. Further study should focus on identifying other cytokines associated with *H. pylori* infection and FRVE therapy.

FRVE exhibited more potent activity against *H. pylori* compared to the standard triple therapy comprising two antibiotic agents and a proton pump inhibitor (Figure 3). In addition, FRVE significantly reduced *H. pylori*-induced gastritis, although such effect was not due to altered IL-1β or TNF-α expression in mice. Furthermore, the standard triple therapy together with a low concentration of FRVE exerted synergistic effect. Therefore, FRVE might be used as a potential adjuvant therapeutic agent for treating *H. pylori*-induced gastric disease (Figure 6).

**ACKNOWLEDGMENT**

This research was supported by Hallym University Research Fund, 2016 Research Grant from Kangwon National University (No. 277520160292), Cooperative Research Program for Agriculture Science and Technology Development (Project No. PJ009859) Rural Development Administration, Republic of Korea, and Basic Science Research Program (2020R1A6A1A03043026) through the NRF funded by the Ministry of Education.

**ORCID**

Myong Jo Kim https://orcid.org/0000-0003-4378-4071

Ki Tae Suk https://orcid.org/0000-0002-9206-9245

**REFERENCES**

Akbari, G. (2020). Molecular mechanisms underlying gallic acid effects against cardiovascular diseases: An update review. *Avicenna Journal of Phytomedicine*, 10(1), 11-23.

Bang, C. S., Hong, S. H., Suk, K. T., Kim, J. B., Han, S. H., Sung, H., Kim, E. J., Kim, M. J., Kim, M. Y., Baik, S. K., & Kim, D. J. (2014). Effects of Korean Red Ginseng (Panax ginseng), urushiol (Rhus verniciflua Stokes), and probiotics (Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052) on the gut-liver axis of alcoholic liver disease. *Journal of Ginseng Research*, 38(3), 167-172. https://doi.org/10.1016/j.jgr.2014.04.002

Brown, J. C., Wang, J., Kasman, L., Jiang, X., & Haley-Zitlin, V. (2011). Activities of muscadine grape skin and quercetin against Helicobacter pylori infection in mice. *Journal of Applied Microbiology*, 110(1), 139-146. https://doi.org/10.1111/j.1365-2672.2010.04870.x

Choi, H. S., Kim, M. K., Choi, Y. K., Shin, Y. C., Cho, S. G., & Ko, S. G. (2016). Rhus verniciflua Stokes (RVS) and butein induce apoptosis of paclitaxel-resistant SKOV-3/PAX ovarian cancer cells through inhibition of AKT phosphorylation. *BMC Complementary and Alternative Medicine*, 16, 122. https://doi.org/10.1186/s12906-016-1103-3

Choi, H.-S., Kim, M.-K., Park, H.-S., Yun, S.-E., Mun, S.-P., Kim, J.-S., & Kim, S.-J. (2007). Biological detoxification of lacquer tree (Rhus verniciflua Stokes) stem bark by mushroom species. *Food Science and Biotechnology*, 16(4), 935-942.

Choi, H. S., Seo, H. S., Kim, S. R., Choi, Y. K., Shin, Y. C., & Ko, S. G. (2014). Anti-inflammatory and anti-proliferative effect of herbal medicines (APR) in RAW264.7 cells. *Molecular Medicine Reports*, 9(5), 1569-1574. https://doi.org/10.3892/mmr.2014.2033

Choi, H.-S., Yeo, S.-H., Jeong, S.-T., Choi, J.-H., Park, H.-S., & Kim, M.-K. (2012). Preparation and Characterization of Urushiol Free Fermented Rhus verniciflua Stem Bark (FRVSB) Extracts. *Korean Journal of Food Science and Technology*, 44(2), 173-178. https://doi.org/10.9721/KJFST.2012.44.2.173

Daglia, M., Di Lorenzo, A., Nabavi, S. F., Talas, Z. S., & Nabavi, S. M. (2014). Polyphenols: Well beyond the antioxidant capacity: Gallic acid and related compounds as neuroprotective agents: You are what you eat! *Current Pharmaceutical Biotechnology*, 15(4), 362-372.

Dixon, M. F., Genta, R. M., Yardley, J. H., & Correa, P. (1996). Classification and Grading of Gastritis. *The American Journal of Surgical Pathology*, 20(10), 1161-1181.

Ermis, F., & Senocak Tasci, E. (2015). Current Helicobacter pylori treatment in 2014. *World Journal of Methodology*, 5(2), 101-107. https://doi.org/10.5662/wjm.v5.i2.101

Gong, E. J., Yun, S. C., Jung, H. Y., Lim, H., Choi, K. S., Ahn, J. Y., & Kim, J. H. (2014). Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: Is it time to change? *Journal of Korean Medical Science*, 29(5), 704-713. https://doi.org/10.3346/jkms.2014.29.5.704

Hyttö, M., Szabó, D., Piipponen, N., Korhonen, E., Honkakoski, P., Kaarniranta, K., Petrovskii, G., & Kauppinen, A. (2017). Two dietary polyphenols, fisetin and luteolin, reduce inflammation but augment DNA damage-induced toxicity in human RPE cells. *Journal of Nutritional Biochemistry*, 42, 37-42. https://doi.org/10.1016/j.jnutbio.2016.12.014

Jang, I.-S., Park, J.-W., Jo, E.-B., Cho, C.-K., Lee, Y.-W., Yoo, H.-S., Park, J., Kim, J., Jang, B.-C., & Choi, J.-S. (2016). Growth inhibitory and apoptosis-inducing effects of allergen-free Rhus verniciflua Stokes extract on A549 human lung cancer cells. *Oncology Reports*, 36(5), 3037-3043. https://doi.org/10.3892/or.2016.5131

Jeong, S.-J., Park, J.-G., Kim, S., Kweon, H. Y., Seo, S., Na, D.-S., Lee, D., Hong, C. Y., Na, C.-S., Dong, M.-S., & Oh, G. T. (2015). Extract of Rhus verniciflua stem protects the diet-induced hyperlipidemia in mice. *Archives of Pharmacal Research*, 38(11), 2049–2058. https://doi.org/10.1007/s12272-015-0579-6

Jin, C. H., Shin, E. J., Park, J. B., Jang, C. G., Li, Z., Kim, M. S., & Kim, H. C. (2009). Fustin flavonoid attenuates beta-amyloid (1-42)-induced learning impairment. *Journal of Neuroscience Research*, 87(16), 3658-3670. https://doi.org/10.1002/jnr.22159

Kang, S. Y., Kang, J. Y., & Oh, M. J. (2012). Antiviral activities of flavonoids isolated from the bark of Rhus verniciflua stalks against fish pathogenic viruses In Vitro. *The Journal of Microbiology*, 50(2), 293–300. https://doi.org/10.1007/s12275-012-2068-7

Lee, D. S., Jeong, G. S., Li, B., Park, H., & Kim, Y. C. (2010). Anti-inflammatory effects of sulfuretin from Rhus verniciflua Stokes via the induction of heme oxygenase-1 expression in murine macrophages. *International Immunopharmacology*, 10(8), 850–858. https://doi.org/10.1016/j.intimp.2010.04.019

Lee, M. S., Kim, J. S., Cho, S. M., Lee, S. O., Kim, S. H., & Lee, H. J. (2015). Fermented Rhus verniciflua Stokes Extract Exerts an...
Antihepatic Lipogenic Effect in Oleic-Acid-Induced HepG2 Cells via Upregulation of AMP-Activated Protein Kinase. *Journal of Agriculture and Food Chemistry*, 63(32), 7270–7276. https://doi.org/10.1021/acs.jafc.5b01954

Lee, S., Kim, K., Jung, H., Lee, S., Cheon, S., Kim, S., & Choi, W. (2011). Efficacy and safety of standardized allergen-removed Rhus verniciflua Stokes extract in patients with advanced or metastatic pancreatic cancer: A Korean single-center experience. *Oncology*, 81(5–6), 312–318. https://doi.org/10.1159/000334695

Leotoing, L., Wauquier, F., Guicheux, J., Miot-Noirault, E., Wittrant, Y., & Coxam, V. (2013). The polyphenol fisetin protects bone by repressing NF-kappaB and MKP-1-dependent signaling pathways in osteoclasts. *PLoS One*, 8(7), e68388. https://doi.org/10.1371/journal.pone.0068388

Loughlin, M. F., Ala'Aldeen, D. A., & Jenks, P. J. (2003). Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice. *Journal of Antimicrobial Chemotherapy*, 51(2), 367–371. https://doi.org/10.1093/jac/dkg057

Navabi, N., Johansson, M. E., Raghavan, S., & Linden, S. K. (2013). Helicobacter pylori infection impairs the mucin production rate and turnover in the murine gastric mucosa. *Infection and Immunity*, 81(3), 829–837. https://doi.org/10.1128/IAI.01000-12

Park, B. C., Lee, Y. S., Park, H. J., Kwak, M. K., Yoo, B. K., Kim, J. Y., & Kim, J. A. (2007). Protective effects of fustin, a flavonoid from Rhus verniciflua Stokes, on 6-hydroxydopamine-induced neuronal cell death. *Experimental & Molecular Medicine*, 39(3), 316–326. https://doi.org/10.1038/emm.2007.35

Ren, Q., Guo, F., Tao, S., Huang, R., Ma, L., & Fu, P. (2020). Flavonoid fisetin alleviates kidney inflammation and apoptosis via inhibiting Src-mediated NF-kappaB p65 and MAPK signaling pathways in septic AKI mice. *Biomedicine & Pharmacotherapy*, 122, 109772. https://doi.org/10.1016/j.biopha.2019.109772

Sapkota, K., Kim, S., Kim, M. K., & Kim, S. J. (2010). A detoxified extract of Rhus verniciflua Stokes upregulated the expression of BDNF and GDNF in the rat brain and the human dopaminergic cell line SH-SY5Y. *Bioscience, Biotechnology, and Biochemistry*, 74(10), 1997–2004. https://doi.org/10.1271/bbb.100165

Schenk, B. E., Kuipers, E. J., Nelis, G. F., Bloemena, E., Thijss, J. C., Snel, P., & Meuwissen, S. G. (2000). Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. *Gut*, 46(5), 615–621. https://doi.org/10.1136/gut.46.5.615

Shin, S.-H., Koo, K.-H., Bae, J.-S., Cha, S.-B., Kang, I.-S., Kang, M.-S., Kim, H.-S., Heo, H.-S., Park, M.-S., Gil, G.-H., Lee, J.-Y., Kim, K.-H., Li, Y., Lee, H.-K., Song, S.-W., Choi, H.-S., Kang, B.-H., & Kim, J.-C. (2013). Single and 90-day repeated oral dose toxicity studies of fermented Rhus verniciflua stem bark extract in Sprague-Dawley rats. *Food and Chemical Toxicology*, 55, 617–626. https://doi.org/10.1016/j.fct.2013.01.043

Suarez, G., Reyes, V. E., & Beswick, E. J. (2006). Immune response to H. pylori. *World Journal of Gastroenterology*, 12(35), 5593–5598.

Suk, K. T., Baik, S. K., Kim, H. S., Park, S. M., Paeng, K. J., Uh, Y., Jang, I. H., Cho, M. Y., Choi, E. H., Kim, M. J., & Ham, Y. L. (2011). Antibacterial effects of the urushiol component in the sap of the lacquer tree (Rhus verniciflua Stokes) on Helicobacter pylori. *Helicobacter*, 16(6), 434–443. https://doi.org/10.1111/j.1523-5378.2011.00864.x

Testerman, T. L., & Morris, J. (2014). Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. *World Journal of Gastroenterology*, 20(36), 12781–12808. https://doi.org/10.3748/wjg.v20.i36.12781

Zhou, D., Yang, Q., Tian, T., Chang, Y., Li, Y., Duan, L.-R., Li, H., & Wang, S.-W. (2020). Gastroprotective effect of gallic acid against ethanol-induced gastric ulcer in rats: Involvement of the Nrf2/HO-1 signaling and anti-apoptosis role. *Biomedicine & Pharmacotherapy*, 126, 110075. https://doi.org/10.1016/j.biopha.2020.110075

How to cite this article: Kim S, Shin SP, Kim SK, et al. Fermented-*Rhus verniciflua* extract ameliorate *Helicobacter pylori* eradication rate and gastritis. *Food Sci Nutr*. 2021;9:900–908. https://doi.org/10.1002/fsn3.2055